Targeting TBK1 and CARM1 to Combat Lung Adenocarcinoma
Abstract
This proposal attempts to test the efficacy of new drugs and drug combinations in preventing the growth of lung cancer. A large majority of lung cancers are correlated with tobacco smoking, and such cancers tend to have alterations in a cancer promoting gene, K-Ras. We propose to test the theory that using three different inhibitors, or their combination, will prevent the growth of such tumors. These inhibitors are known to reduce the levels or inhibit the activity of proteins like CARM1, TBK1, and Raf1. Experiments will be conducted on cultured lung cancer cells as well as in mice. These studies will address the LCRP Area of Emphasis, “Identify innovative strategies for the treatment of lung cancer.” We expect that the successful completion of these studies will establish whether the proposed strategies will be effective in combating lung cancer. While some of the drugs tested in the combination are known to be safe for human use, it is essential to assess their safety when used in combination therapy. Once this is established to be safe, this approach would be useful to combat lung cancer in patients in the near future. Further, the proposed studies will also reveal the molecular events that drive lung cancer and how inhibiting specific molecules affects the different steps of tumor growth. These studies will be especially beneficial to active Service members and Veterans, since smoking is more prevalent among them compared to the general population.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Mar 10, 2021
- Source ID
- W81XWH2010587
Entities
People
- Srikumar Chellappan
Organizations
- H. Lee Moffitt Cancer Center & Research Institute
- United States Army